Breaking News, Financial News

Financial Report: Elan 4Q

FY09 revenue from the Biopharmaceuticals business was up 20% to $837.1 million and for 4Q09 was up 28% to $231.9 million.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Elan 4Q 4Q Revenues: $300 million (+11%) 4Q Loss: $57.7 million (earnings were $169.5 million in 4Q08) FY Revenues: $1.1 billion (+11%) FY Loss: $176.2 million (loss of $71.0 million FY08) Comments: FY09 revenue from the Biopharmaceuticals business was up 20% to $837.1 million and for 4Q09 was up 28% to $231.9 million. Revenue growth was driven by Tysabri sales, up 30% for the year to $724.3 million, and for the quarter sales were $200.5 million (+32%). Azactam sales w...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters